Need Assistance?
  • US & Canada:
  • UK: +


* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

A synthetic pentapeptide that mimics endogenous gastrin when given parenterally. It functions via stimulating the secretion of gastric acid, pepsin, and intrinsic factor.

Peptide Inhibitors
Catalog number
CAS number
Molecular Formula
Molecular Weight
(3S)-4-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-2-[[(2S)-3-(1H-indol-3-yl)-2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoylamino]propanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-oxobutanoic acid
AY 6608; ICI 50123; NSC 367746; Boc-(β-Ala13)-Gastrin (13-17); Boc-β-Ala-CCK-4; Peptavlon; D01631
Solid Powder
1.303 g/cm3
Melting Point
229-230° (dec)
Boiling Point
1196.6°C at 760 mmHg
Store at -20°C
Soluble in DMSO
InChI Key
Canonical SMILES
1.Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M1, Dowen S, Turnbull G, van den Berg F, Zhao CM, Chen D, Black J. Br J Clin Pharmacol. 2015 May;79(5):744-55. doi: 10.1111/bcp.12534.
AIMS: To compare gastric acid suppression by netazepide, a gastrin/CCK2 receptor antagonist, with that by a proton pump inhibitor (PPI), and to determine if netazepide can prevent the trophic effects of PPI-induced hypergastrinaemia.
2.Esomeprazole inhibits the pentagastrin-stimulated secretion of gastric acid in healthy Japanese volunteers.
Maejima R1, Koike T, Nakagawa K, Iijima K, Shimosegawa T. Tohoku J Exp Med. 2015;235(3):249-53. doi: 10.1620/tjem.235.249.
Gastroesophageal reflux disease (GERD) is a common disease, in which the reflux of gastric acid causes mucosal damage of the esophagus and/or troublesome symptoms. Esomeprazole, a proton pump inhibitor, has been used for treatment of GERD in Japan since 2011; namely, only little is known about its effect on gastric acid secretion in Japanese. We, therefore, assessed the relationship between dose and timing of esomeprazole administration and gastric acid inhibition in 11 healthy male Japanese volunteers by directly examining gastric acid secretion capacity. In this randomized, open-label, three-way crossover study, the subjects were dosed with esomeprazole 10 mg or 20 mg once a day (q.d.), or 20 mg twice a day (b.i.d.) for 14 days, and pentagastrin-stimulated gastric acid secretion was measured by endoscopic gastrin test. At steady states, gastric acid inhibition rates were significantly higher in esomeprazole 20 mg b.i.d. (median 100.0%, interquartile range [IQR] 99.
3.Stimulation of Mucin, Mucus, and Viscosity during Lubiprostone in Patients with Chronic Constipation may Potentially Lead to Increase of Lubrication.
Majewski M1, Sarosiek I2, Wallner G1, Edlavitch SA3, Sarosiek J2. Clin Transl Gastroenterol. 2014 Dec 18;5:e66. doi: 10.1038/ctg.2014.19.
OBJECTIVES: The purpose of this clinical trial was to explore whether lubiprostone increases the rate of mucus and mucin secretion and its viscosity in chronic constipation (CC) patients. The secretion of chloride (CS) into the gastrointestinal tract lumen is pivotal in the body's ability to process non-digestible food components. CS sets the optimal rate of hydration for non-digestible food components, their fluidity, and their adequate propulsion along the alimentary tract. Chloride is also instrumental in the secretion of alimentary tract mucus, and the formation of a gel-like, viscous mucus-buffer layer. This layer acts as the first line and vanguard of the mucosal barrier. This barrier is essential in mucosal lubrication and protection. Lubiprostone, a novel chloride channel stimulator ClC-2, is currently approved for the treatment of CC. Its impact on mucus, mucus secretion, and viscosity is not established.
4.Suspension Culture Alters Insulin Secretion in Induced Human Umbilical Cord Matrix-Derived Mesenchymal Cells.
Seyedi F1, Farsinejad A2, Nematollahi-Mahani SA3, Eslaminejad T4, Nematollahi-Mahani SN5. Cell J. 2016 Spring;18(1):52-61. Epub 2016 Apr 4.
OBJECTIVE: Worldwide, diabetes mellitus (DM) is an ever-increasing metabolic disorder. A promising approach to the treatment of DM is the implantation of insulin producing cells (IPC) that have been derived from various stem cells. Culture conditions play a pivotal role in the quality and quantity of the differentiated cells. In this experimental study, we have applied various culture conditions to differentiate human umbilical cord matrix-derived mesenchymal cells (hUCMs) into IPCs and measured insulin production.
Online Inquiry
Verification code
Inquiry Basket